A5029356365- Glioma Diagnosis and Treatment
- Vascular Malformations Diagnosis and Treatment
- Brain Metastases and Treatment
- Radiomics and Machine Learning in Medical Imaging
- Cancer Genomics and Diagnostics
- Meningioma and schwannoma management
- Neuroblastoma Research and Treatments
- MicroRNA in disease regulation
- Single-cell and spatial transcriptomics
- Intracranial Aneurysms: Treatment and Complications
- MRI in cancer diagnosis
- Medical Imaging Techniques and Applications
- Liver Disease and Transplantation
- Neuroinflammation and Neurodegeneration Mechanisms
- Gastroesophageal reflux and treatments
- Cerebrovascular and Carotid Artery Diseases
- Immune cells in cancer
- Chromatin Remodeling and Cancer
- Fetal and Pediatric Neurological Disorders
- Synthesis of Organic Compounds
- Spinal Fractures and Fixation Techniques
- Genetic and rare skin diseases.
- Angiogenesis and VEGF in Cancer
- Histiocytic Disorders and Treatments
- Cardiovascular, Neuropeptides, and Oxidative Stress Research
South Osaka Neurosurgical Hospital
2025
Kyushu University
2014-2023
Nippon Steel (Japan)
1998
Kyoto Pharmaceutical University
1995
Conventional genetic analyzers require surgically obtained tumor tissues to confirm the molecular diagnosis of diffuse glioma. Recent technical breakthroughs have enabled increased utilization cell-free DNA (ctDNA) in body fluids as a reliable resource for various cancers. Here, we tested application chip-based digital PCR system less invasive (i.e., liquid biopsy) glioma using cerebrospinal fluid (CSF).CSF samples from 34 patients with were collected surgical field during craniotomy....
Abstract Objective Accumulating evidence from recent molecular diagnostic studies has indicated the prognostic significance of various genetic markers for patients with glioblastoma (GBM). To evaluate impact such on prognosis, we retrospectively analyzed outcomes IDH ‐wildtype GBM in our institution. In addition, to assess bevacizumab (BEV) treatment, compared overall survival (OS) between pre‐ and post‐BEV eras. Methods We data 100 adult (over 18 years old) database February 2006 October...
BackgroundAt our hospital, we use the flow re-direction endoluminal device (FRED) to treat vertebral artery (VA) aneurysms. Some reports suggest that treatment efficacy of FRED may be lower in patients with fusiform-type At compared outcomes for both fusiform- and saccular-type aneurysms occurring at posterior inferior cerebellar bifurcation.MethodsWe included 29 245 treated VA (9 saccular 20 fusiform) between June 2020 November 2022. We assessed occlusion rates background factors, including...
Targeting the unique glioma immune microenvironment is a promising approach in developing breakthrough immunotherapy treatments. However, recent advances immunotherapy, including development of checkpoint inhibitors, have not improved outcomes patients with glioma. A way monitoring biological activity cells neural tissues affected by should be developed to address this lack sensitivity immunotherapy. Thus, study, we sought examine feasibility non-invasive glioma-associated...
Rapid technological advances in molecular biology, including next-generation sequencing, have identified key genetic alterations central nervous system (CNS) tumors. Accordingly, the fifth edition of World Health Organization (WHO) CNS tumor classification was published 2021. We analyzed 303 patients with diffuse glioma using an amplicon-based glioma-tailored gene panel for detecting 1p/19q codeletion and driver mutations such as IDH1/2, TERTp, EGFR, CDKN2A/B on a single platform. Within...
Abstract High vascularization is a biological characteristic of glioblastoma (GBM); however, an in-vitro experimental model to verify the mechanism and physiological role vasculogenesis in GBM not well-established. Recently, we established self-organizing vasculogenic using human umbilical vein endothelial cells (HUVECs) co-cultivated with lung fibroblasts (hLFs). Here, exploited this system establish realistic GBM. We developed two polydimethylsiloxane (PDMS) devices, doughnut-hole dish...
We aimed to retrospectively determine the resection rate of fluid-attenuated inversion recovery (FLAIR) lesions evaluate clinical effects supramaximal (SMR) on survival patients with glioblastoma (GBM). Thirty-three adults newly diagnosed GBM who underwent gross total tumor were enrolled. The tumors classified into cortical and deep-seated groups according their contact gray matter. Pre- postoperative FLAIR gadolinium-enhanced T1-weighted imaging volumes measured using a three-dimensional...
Copy number alterations (CNAs) are common in diffuse gliomas and have been shown to diagnostic significance. While liquid biopsy for glioma has widely investigated, techniques detecting CNAs currently limited methods such as next-generation sequencing. Multiplex ligation-dependent probe amplification (MLPA) is an established method copy analysis pre-specified loci. In this study, we investigated whether could be detected by MLPA using patients' cerebrospinal fluid (CSF).
Although we have shown the clinical benefit of bevacizumab (BEV) in treatment unresectable newly diagnosed glioblastomas (nd-GBM), relationship between early radiographic response and survival outcome remains unclear. We performed a volumetric study responses nd-GBM treated with BEV.Twenty-two patients BEV during concurrent temozolomide radiotherapy were analyzed. An experienced neuroradiologist interpreted on fluid-attenuated inversion recovery (FLAIR) gadolinium-enhanced T1-weighted images...
The mutation p.K27M in H3F3A (H3 K27M mutation) is mainly detected diffuse midline glioma. However, recent studies have demonstrated that H3 could also be observed a subset of gangliogliomas. Importantly, most K27-mutated ganglioglioma cases harbor BRAF V600E mutation. Herein, we report rare case K27M-mutated grade 3 without arising the medial temporal lobe an elderly man. A small biopsy specimen was sampled. pathological diagnosis astrocytoma. tumor progressed gradually during 18-month...
Abstract Background In the treatment for glioblastoma (GBM), modalities, such as bevacizumab (BEV) and carmustine wafers implants have been approved in Japan since 2013. However, it is unclear whether a trend complexity can accelerate centralization. The aim of this study was to reveal current GBM Japan. Methods We used diagnostic procedure combination (DPC) database analyze data 1,774 patients from 305 institutions between April 2016 March 2019. To situations associated with first-line BEV...
Glioblastoma (GBM) most commonly appears to be intraparenchymal tumor, and intraventricular GBMs are rarely reported. In previous reports, the sites of origin were not identified. Here, we report a rare case mucin-producing GBM in 73-year-old woman who had strongly enhancing tumor right anterior horn lateral ventricle. The previously been identified one half years ago as small asymptomatic lesion attached septum pellucidum. It documented gradually enlarge during subsequent follow-up...
Angiogenesis is regulated by various factors. In particular, VEGF and basic FGF are of much importance. We found that 8-(3-oxo-4,5,6-trihydroxy-3h-xanthen-9-yl)-1-naphthoic acid inhibited the binding to KDR/Flk-1 (VEGF receptor-2) or Flt-1 receptor-1) it MAPK phosphorylation in HUVEC induced but not EGF. might be used as an inhibitor signal transduction.
Abstract INTRODUCTION First-line bevacizumab (BEV) is now available as a treatment option for glioblastoma (GBM) patients with severe clinical conditions in Japan. However, the survival benefits remain controversial. As we have emphasized combined effect of BEV and radiation therapy, strategies; 1) first-line add-on to TMZ-radiation unresectable GBMs 2) re-irradiation using IMRT under administration recurrent GBMs, been positively applied. To elucidate these potential benefits,...
Abstract Kyushu University Hospital was designated a Cancer Genome Core in April 2018, and the multi-gene panel test has been introduced since August 2019. The expert held for 21 cases of central nervous system (11 adult glioma, 5 pediatric brain tumors, extramedullary tumors). Actionable gene abnormalities were newly detected two cases. First case is epithelioid glioblastoma with BRAF V600E mutation, second embryonal tumor VCL-ALK fusion. For first case, BRAF/MEK inhibitor can be used by...
Abstract Introduction: There exist controversies on recurrence and aggressiveness after use of first-line bevacizumab (BEV) which has been approved in Japan proven to be beneficial. Therefore, we analyzed the clinical impact BEV approval by investigating overall course glioblastoma (GBM) relapse pattern. Methods: We included 100 patients with IDH-wildtype GBM between September 2006 February 2018 from our institution. They were subdivided into pre-BEV (n=51) post-BEV (n=49) groups. Overall,...